Abstract
The humoral arm of the immune system provides robust protection against extracellular pathogens via the production of antibody molecules that neutralize or facilitate the destruction of microorganisms. However, the humoral immune system also provides a significant barrier to solid organ transplantation due to the antibody-mediated recognition of non-self proteins and carbohydrates expressed on transplanted organs. Historically, the presence of donor-specific antibodies (DSA) that recognize donor HLA molecules, incompatible ABO blood group antigens and other endothelial or xenogeneic antigens was considered a contraindication to transplantation. However, recent advances in antibody testing and immunosuppressive therapies have made it possible to cross certain antibody barriers successfully. In this article, we review our current understanding of antibody-mediated processes in solid organ transplantation and discuss the clinically available treatment options for preventing and treating antibody-mediated rejection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 224-234 |
| Number of pages | 11 |
| Journal | Seminars in immunology |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2011 |
Keywords
- ABO incompatible
- Anti-endothelial antibody
- Antibody mediated rejection
- HLA antibody
- Humoral rejection
- Positive crossmatch
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology